Answers are grounded in this paper and cite their sources.
Case report reveals acute mechanical prosthetic valve thrombosis linked to probable VITT following ChAdOx1 nCoV-19 vaccination, highlighting the need for prompt clinical management.
The ChAdOx1 nCoV-19 adenoviral vector-based vaccine was the first to be approved against COVID-19 in India. Vaccine induced thrombotic thrombocytopenia (VITT) is a rare but serious adverse effect of the ChAdOx1 nCoV-19 vaccine, causing widespread thrombosis and thrombocytopenia. A 22-year-old patient, who had undergone mechanical mitral valve replacement, presented to us one week after administration of 1st dose of the ChAdOx1 nCoV-19 Coronavirus vaccine with acute prosthetic heart valve thrombosis (PVT). Laboratory investigations revealed thrombocytopenia and high D-Dimer levels, suggestive of probable VITT. In this report, we highlight the importance of identification of VITT as a cause of PVT and discuss management options.
No takes yet. Share an insight, caveat, or question.
Jain et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: